{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:33:15Z","timestamp":1790065995232,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40257-025-00973-5","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T08:16:22Z","timestamp":1755159382000},"page":"1055-1059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9255-8196","authenticated-orcid":false,"given":"Zoe","family":"Apalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6657-6630","authenticated-orcid":false,"given":"Katya","family":"Harfmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"issue":"2","key":"973_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81\u20139.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"973_CR2","first-page":"59","volume":"20","author":"DA Lintzeri","year":"2022","unstructured":"Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume-Peytavi U. Alopecia areata\u2014Current understanding and management. J Dtsch Dermatol Ges. 2022;20(1):59\u201390.","journal-title":"J Dtsch Dermatol Ges"},{"key":"973_CR3","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"973_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jdv.19768","volume":"38","author":"L Rudnicka","year":"2024","unstructured":"Rudnicka L, Arenbergerova M, Grimalt R, Ioannides D, Katoulis AC, Lazaridou E, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"973_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.det.2012.08.010","volume":"31","author":"A Alkhalifah","year":"2013","unstructured":"Alkhalifah A. Alopecia areata update. Dermatol Clin. 2013;31(1):93\u2013108.","journal-title":"Dermatol Clin"},{"issue":"10387","key":"973_CR6","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"issue":"18","key":"973_CR7","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"key":"973_CR8","unstructured":"Sun Pharmaceutical Industries Ltd. U.S. FDA approves LEQSELVI\u2122 (deuruxolitinib), an oral JAK inhibitor for the treatment of severe alopecia areata. 2024. https:\/\/sunpharma.com\/wp-content\/uploads\/2024\/07\/Sunpharma-LEQSELVI-Approval-Scenario-Press-Release.pdf. Accessed 16 Oct 2024."},{"key":"973_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13555-022-00711-3","volume":"12","author":"B King","year":"2022","unstructured":"King B, Senna MM, Ohyama M, Tosti A, Sinclair RD, Ball S, et al. Defining severity in alopecia areata: current perspectives and a multidimensional framework. Dermatol Ther (Heidelb). 2022;12:825\u201334.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"973_CR10","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jaad.2016.08.042","volume":"75","author":"EA Olsen","year":"2016","unstructured":"Olsen EA, Canfield D. Salt II: a new take on the severity of alopecia tool (salt) for determining percentage scalp hair loss. J Am Acad Dermatol. 2016;75:1268\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"973_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines\u2013Part II. J Am Acad Dermatol. 2004;51(3):440\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"973_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.10.048","volume":"79","author":"EA Olsen","year":"2018","unstructured":"Olsen EA, Roberts J, Sperling L, Tosti A, Shapiro J, McMichael A, et al. Objective outcome measures: collecting meaningful data on alopecia areata. J Am Acad Dermatol. 2018;79(3):1\u201319.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"973_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","volume":"86","author":"BA King","year":"2022","unstructured":"King BA, Mesinkovska NA, Craiglow B, Kindred C, Ko J, McMichael A, et al. Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort. J Am Acad Dermatol. 2022;86(2):359\u201364.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"973_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jaad.2016.10.002","volume":"76","author":"KA McDonald","year":"2017","unstructured":"McDonald KA, Shelley AJ, Colantonio S, Beecker J. Hair pull test: evidence-based update and revision of guidelines. J Am Acad Dermatol. 2017;76(3):472\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"973_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/jamadermatol.2023.5869","volume":"160","author":"A Moussa","year":"2024","unstructured":"Moussa A, Bennett M, Wall D, Meah N, York K, Bokhari L, et al. The Alopecia Areata Severity and Morbidity Index (ASAMI) study: results from a global expert consensus exercise on determinants of alopecia areata severity. JAMA Dermatol. 2024;160(3):341\u201350.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"973_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/jamadermatol.2020.5732","volume":"157","author":"A Creadore","year":"2021","unstructured":"Creadore A, Manjaly P, Li SJ, Tkachenko E, Zhou G, Joyce C, et al. Evaluation of stigma toward individuals with alopecia. JAMA Dermatol. 2021;157(4):392\u20138.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"973_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","volume":"75","author":"LY Liu","year":"2016","unstructured":"Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol. 2016;75(4):806-12.e3.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"973_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","volume":"4","author":"NVJ Aldhouse","year":"2020","unstructured":"Aldhouse NVJ, Kitchen H, Knight S, Macey J, Nunes FP, Dutronc Y, et al. \u201c\u2018You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed:\u201d a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020;4(1):76.","journal-title":"J Patient Rep Outcomes."},{"issue":"1","key":"973_CR19","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20(1):S62\u20138.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"973_CR20","first-page":"106","volume":"13","author":"P Layegh","year":"2010","unstructured":"Layegh P, Arshadi HR, Shahriari S, Nahidi Y. A comparative study on the prevalence of depression and suicidal ideation in dermatology patients suffering from psoriasis, acne, alopecia areata and vitiligo. Iran J Dermatol. 2010;13:106\u201311.","journal-title":"Iran J Dermatol."},{"issue":"3","key":"973_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)\u2014A simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"973_CR22","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jisp.2017.10.009","volume":"19","author":"TR Mendoza","year":"2018","unstructured":"Mendoza TR, Osei J, Duvic M. The utility and validity of the Alopecia Areata Symptom Impact Scale in measuring disease-related symptoms and their effect on functioning. J Investig Dermatol Symp Proc. 2018;19(1):S41\u20136.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"4","key":"973_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/bjd.14361","volume":"174","author":"JR Olsen","year":"2016","unstructured":"Olsen JR, Gallacher J, Finlay AY, Piguet V, Francis NA. Quality of life impact of childhood skin conditions measured using the Children\u2019s Dermatology Life Quality Index (CDLQI): a meta-analysis. Br J Dermatol. 2016;174(4):853\u201361.","journal-title":"Br J Dermatol"},{"issue":"2","key":"973_CR24","first-page":"343","volume":"12","author":"JA Smith","year":"2001","unstructured":"Smith JA. The impact of skin disease on the quality of life of adolescents. Adolesc Med. 2001;12(2):343\u201353.","journal-title":"Adolesc Med"},{"issue":"8","key":"973_CR25","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/jdv.18848","volume":"37","author":"M Prendke","year":"2023","unstructured":"Prendke M, Kanti-Schmidt V, Wilborn D, Hillmann K, Singh R, Vogt A, et al. Quality of life in children and adolescents with alopecia areata\u2014A systematic review. J Eur Acad Dermatol Venereol. 2023;37(8):1521\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"973_CR26","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.jaad.2020.09.028","volume":"84","author":"N Meah","year":"2021","unstructured":"Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Asz-Sigall D, et al. The Alopecia Areata Consensus of Experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata. J Am Acad Dermatol. 2021;84(6):1594\u2013601.","journal-title":"J Am Acad Dermatol"},{"key":"973_CR27","unstructured":"Peeva E, Banerjee A. Oral Janus kinase inhibitors PF-06700841 and PF-06651600 provide clinically evident therapeutic effect at 4 and 6 weeks in patients with alopecia areata and greater efficacy over 24 weeks in patients with a shorter duration of their current alopecia episode. American Academy of Dermatology Annual Meeting; 2019; Washington, DC, USA."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00973-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:45:36Z","timestamp":1763048736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00973-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["973"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00973-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"15 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This vodcast was sponsored by Pfizer Inc. Medical writing support was provided by Kirstin Anderson of Nucleus Global, an Inizio company, and funded by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Zoe Apalla and Katya Harfmann declare that they have no conflicts of interest that might be relevant to the contents of this vodcast.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to participate\/publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in (1) vodcast conception; (2) editing and revising the vodcast script drafts; and (3) providing intellectual content of critical importance to the work described. All authors read and approved the final manuscript and therefore meet the criteria for authorship in accordance with the International Committee of Medical Journal Editors guidelines. All authors take responsibility for the integrity of the work and have given their approval for this version to be published.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}